| 中文名称 | A-366 |
| 英文名称 | 5'-Methoxy-6'-[3-(1-pyrrolidinyl)propoxy]spiro[cyclobutane-1,3'-[3H]indol]-2'-amine |
| CAS号 | 1527503-11-2 |
| 分子式 | C19H27N3O2 |
| 分子量 | 329.44 |
| EINECS号 | 808-907-0 |
| 沸点 | 533.6±60.0 °C(Predicted) |
| 密度 | 1.29±0.1 g/cm3(Predicted) |
| 溶解度 | DMSO:50 mg/mL(151.77 mM;需要超声波) |
| 形态 | 粉末 |
| 酸度系数(pKa) | 10.18±0.20(Predicted) |
| 颜色 | 白色至米色 |
| 危险品运输编号 | UN 3077 9 / PGIII |
| WGK Germany | 3 |
A-366 (0.01-10 μM; 14 days) induces differentiation and affects viability in MV4;11 cells.
A-366 (0.3-3 μM; 72 hours) reduces the total levels of H3K9me2 in a time and concentration dependent manner with a cellular EC50 of ~300 nM in PC-3 prostate adenocarcinoma cells. A-366 (0.01-10 μM; 4 days; HL-60 cells) results in a dose-dependent differentiation and a corresponding decrease in proliferation. DNA content analysis of A-366-treated HL-60 cells showed an accumulation of cells in G1 consistent with cytostasis.
Cell Viability Assay
| Cell Line: | MV4;11 cells |
| Concentration: | 0.01-10 μM |
| Incubation Time: | 14 days |
| Result: | Resulted in inhibited proliferation and a decrease in viability corresponding to the dose response observed for CD11b staining. |
A-366 (30 mg/kg; osmotic mini-pump; daily for 14 days) treatment of MV4;11 xenografts elicits growth inhibition.
| Animal Model: | 6-8 week old SCID-beige female mice (MV4;11 xenografts) |
| Dosage: | 30 mg/kg |
| Administration: | By osmotic mini-pump; daily for 14 days |
| Result: | A modest 45% tumor growth inhibition resulting from A-366 treatment in this model. |